Skip to content

Xplorer™ program

Biomarker Xplorer™

Find the markers that separate two groups, and confirm them before you build on them.

Biomarker Xplorer™ reads DNA, RNA and proteins against the same question, from the isolation of biomolecules to a short list of candidates confirmed by targeted quantification. Designed by GENXMAP and run in our Marseille laboratories. Single-cell and spatial transcriptomics are available through Transcriptomics 360.

CIR-approved 2026–2028
3
levels of analysis: DNA, RNA, proteins
4
questions: discovery, mechanism, confirmation, decision
9
application areas, from oncology to toxicology

Flagship offer

Transcriptomics 360

One experimental design and one project lead across bulk, single-cell and spatial transcriptomics.

Discover the offerStart a project

What the program answers

The questions it answers

A single data layer, genomic, transcriptomic or proteomic, captures only part of a biological mechanism. Biomarker Xplorer combines them, so a candidate is supported by more than one measurement.

  1. 01

    Discovery

    Which molecular features separate your groups: patients and controls, responders and non-responders, treated and untreated?

  2. 02

    Mechanism

    Which pathways and cell programs sit behind the signature, and do DNA, RNA and protein point the same way?

  3. 03

    Confirmation

    Which candidates hold up when measured by a targeted assay on more samples, or on a cohort they were not derived from?

  4. 04

    Decision

    Which short list is worth developing, and which candidates should be dropped now, with the evidence to say why?

Where it is used

  • Oncology and cancer
  • Rare and genetic diseases
  • Immunology and inflammation
  • Pharmacogenomics and treatment response
  • Experimental models and CRISPR validation
  • Translational research and precision medicine
  • Neurology and neurodegeneration
  • Environment and microbiota
  • Molecular toxicology

Omics layers

Layers combined according to the question

Genomics (DNA)

Somatic and germline variants, copy number and mutational signatures, summarized per sample and per group.

  • WGS · WESgenome, exome
  • Targeted panelsamplicons
  • Copy numbersignatures

Transcriptomics (RNA)

Bulk RNA-seq profiles gene expression in each sample.

  • Bulk RNA-seq
  • Single-cell and spatialthrough Transcriptomics 360

Proteomics

Protein-level quantification by label-free LC-MS/MS, performed on a timsTOF Pro 2 (Bruker), matched against the transcriptomic result.

  • timsTOF Pro 2
  • RNA–protein agreementper candidate

Targeted confirmation

Selected candidates measured by targeted assays on the full sample set, following MIQE and dMIQE guidance.

  • RT-qPCRexpression
  • Digital PCRabsolute quantification
  • Amplicon panelsDNA markers

Single-cell and spatial transcriptomics are available through Transcriptomics 360.

Workflow

How a program runs

  1. 01

    Question and design

    Groups, sample size and the split between discovery and confirmation are set before a single sample is run.

  2. 02

    Isolation and QC

    DNA, RNA and proteins extracted from tissues, blood, cells or biofilms; purity, concentration and integrity (RIN, RQN) checked before anything is sequenced.

  3. 03

    Discovery

    Bulk RNA-seq in our laboratories for global expression profiles, with genomics and proteomics where the question needs them.

  4. 04

    Bioinformatics and integration

    Versioned pipelines, differential analysis, GO, KEGG and Reactome enrichment and multi-omics integration narrow thousands of features to a testable few.

  5. 05

    Targeted confirmation

    The short list is measured by qPCR or dPCR on the full sample set, and read against the question the study started from.

Deliverables

What you receive

Data
FASTQ, alignments, variant and expression matrices, quality-controlled and documented.
Analysis
Differential analysis, enrichment and integration results, with tool versions, parameters and thresholds for every step.
Candidates
A ranked short list, each candidate mapped to a confirmation assay, and a documented no-go on those that did not hold up.
Report
Interpretation written against your question, with publication-ready figures, delivered as a PDF.

Practical terms

Report
PDF with a verifiable, time-stamped fingerprint
Data
Data is hosted in the EU, with backups in France, a separate space per team
Confidentiality
Mutual NDA available before any detail is shared, at no charge
AI
Models on our servers, no data sent to an external AI

Turnaround

Turnaround, in working days from GO

Standard project

4–6 weeks

The usual pace for a project, confirmed in the quote.

Priority

2–4 weeks

When your schedule requires it, agreed at scoping and confirmed in the quote.

Counted in working days from GO, given once samples have passed visual QC on receipt. Larger programs are planned in milestones, each with its own date.

Turnaround times, service by service

Illustrated case study

See the program at work

FAQ

Questions we get asked

What is the difference between discovery and confirmation?

Discovery measures thousands of features on a limited number of samples to find candidates. Confirmation measures a short list by targeted assay (qPCR, dPCR or amplicon panels) on more samples, ideally on a cohort the candidates were not derived from. A candidate that does not hold up is reported as such.

Direct link to this question
Does Biomarker Xplorer include single-cell and spatial transcriptomics?

Not directly. Bulk RNA-seq runs in our Marseille laboratories, alongside genomics and proteomics when the question calls for them. Single-cell and spatial transcriptomics are available through Transcriptomics 360, which runs bulk, single-cell and spatial on one experimental design, under one GENXMAP contract and one project lead.

Direct link to this question
How is proteomics done in a biomarker project?

Proteomics is performed on site by label-free LC-MS/MS with LFQ (label-free quantification) on a timsTOF Pro 2 (Bruker). The protein-level result is set against the transcriptomic result, and a short list of candidates is then confirmed by targeted assay (qPCR, dPCR or amplicon panels) on more samples.

Direct link to this question
Can you look for biomarkers in data we already have?

Yes. Genomic, transcriptomic or proteomic data from an earlier study or another provider can be analyzed and integrated on its own terms. What matters is the biological question and the metadata that came with the data. We tell you what the data can and cannot support before proposing an analysis.

Direct link to this question
How long does a Biomarker Xplorer project take?

A standard project takes 4–6 weeks, or 2–4 weeks with priority handling, counted in working days from GO. GO is given after the visual check of your samples on reception, once the QC report has been generated. Larger programs are planned in milestones confirmed in the quote.

Direct link to this question
Who can see our biomarker data?

Only the people you authorize: each team works in a separate space, with data hosted in the EU and backups in France. A mutual NDA can be signed before any detail is shared, at no charge.

Direct link to this question

A question for this program?

Tell us the question, the samples and the timeline.